SARS-CoV-2: What ’ s in a Name? SARS-CoV-2: What ’ s in a Name?
The name of the new coronavirus that first appeared in China has been evolving to its now official designation: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).Medscape Medical News
Conditions: Coronavirus; SARS-CoV-2 Intervention: Other: Non-Interventional Sponsor: Rutgers, The State University of New Jersey Recruiting
A majority of pregnant women who are diagnosed with coronavirus don't experience more severe illness than the general population, according to a new study.
Luminex can be added to the list of companies that have received Emergency Use Authorization (EUA) for a diagnostic to address the coronavirus (COVID-19) pandemic. The Austin, TX-based firm was granted the designation for the Aries SARS-CoV-2 Assay for the rapid detection of the virus that causes COVID-19. The assay runs on the Aries System, which is cleared by FDA and has the capability of running up to 144 tests per day. Recently Luminex received another EUA in addition to Medical Device Authorization for importation or sale for Health Canada for theÂ NxTAG CoV Extended Panel. The company said the panel is a h...
Radiologists from Singapore are offering their peers strategies learned from...Read more on AuntMinnie.comRelated Reading: Radiology has key role to play in the midst of COVID-19 SBI releases coronavirus social distancing tips ACR posts list of resources for coronavirus outbreak Radiology experts list COVID-19 best practices SDMS proposes anti-infection guidelines
(American Society for Microbiology) No vaccines exist that protect people against infections by coronaviruses, including SARS-CoV-2, which causes COVID-19, or the ones that cause SARS and MERS. As COVID-19 continues to wreak havoc, many labs around the world have developed a laser-like focus on understanding the virus and finding the best strategy for stopping it.
Here is what three studies found about SARS-CoV2 and eyes.
A drug that's been tested against the coronaviruses that cause MERS and SARS and shown to have valuable antiviral properties appears to be potent against the COVID-19 virus as well.
One would hope that it does not require an ongoing pandemic and related hysteria to point out that old people have poorly functioning immune systems, and thus suffer disproportionately the burden of infectious disease. But perhaps it does. The 2017-2018 seasonal influenza, a modestly more severe occurrence of something that happens every year, killed something like 60,000 people in the US alone, with little notice or comment. There is nothing so terrible that it won't be accepted - ignored, even - if it is normal. Floodgates of funding for infectious disease research and development have been opened in response to C...
If there was one glimmer of hope among the alarming number of cases of COVID-19 in the past few months, it was that young children seemed to avoid more serious illness. That trend, which doctors in China first reported, seems to be holding true in the US as well. In the latest Morbidity and Mortality Weekly Report report released today by the Centers for Disease Control (CDC), scientists say that compared to adults, children under the age of 18 are less likely to experience the typical symptoms of infection, including fever, cough and difficulty breathing, and are also less likely to need hospitalization and less likely to...
Condition: SARS-CoV-2 Infection Interventions: Drug: Tocilizumab (TCZ); Drug: Placebo Sponsors: University Hospital Inselspital, Berne; Roche Pharma AG Not yet recruiting